These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 28112184)

  • 21. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
    Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
    BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis.
    Kwon HJ; Kim MS; Kim MJ; Nakajima H; Kim KW
    Int J Cancer; 2002 Jan; 97(3):290-6. PubMed ID: 11774279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chromopeptide A, a highly cytotoxic depsipeptide from the marine sediment-derived bacterium Chromobacterium sp. HS-13-94.
    Zhou Z; Wang X; Zhang H; Sun J; Zheng L; Liu H; Wang J; Shen A; Geng M; Guo Y
    Acta Pharm Sin B; 2015 Jan; 5(1):62-6. PubMed ID: 26579426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
    Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors.
    Saijo K; Imamura J; Narita K; Oda A; Shimodaira H; Katoh T; Ishioka C
    Cancer Sci; 2015 Feb; 106(2):208-15. PubMed ID: 25492515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer.
    Dong J; Zheng N; Wang X; Tang C; Yan P; Zhou HB; Huang J
    Eur J Pharmacol; 2018 Jun; 828():67-79. PubMed ID: 29563065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.
    Tsaur I; Hudak L; Makarević J; Juengel E; Mani J; Borgmann H; Gust KM; Schilling D; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
    J Cell Mol Med; 2015 Aug; 19(8):1795-804. PubMed ID: 25808196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of histone deacetylase on prostate carcinoma.
    Zhang Y; Xu Q; Liu G; Huang H; Lin W; Huang Y; Chi Z; Chen S; Lan K; Lin J; Zhang Y
    Int J Clin Exp Pathol; 2015; 8(11):15030-4. PubMed ID: 26823840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
    Yao Y; Tu Z; Liao C; Wang Z; Li S; Yao H; Li Z; Jiang S
    J Med Chem; 2015 Oct; 58(19):7672-80. PubMed ID: 26331334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Magnolin inhibits prostate cancer cell growth in vitro and in vivo.
    Huang Y; Zou X; Zhang X; Wang F; Zhu W; Zhang G; Xiao J; Chen M
    Biomed Pharmacother; 2017 Mar; 87():714-720. PubMed ID: 28092770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.
    Frønsdal K; Saatcioglu F
    Prostate; 2005 Feb; 62(3):299-306. PubMed ID: 15389787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
    Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
    Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
    Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
    Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
    Lee HY; Lee JF; Kumar S; Wu YW; HuangFu WC; Lai MJ; Li YH; Huang HL; Kuo FC; Hsiao CJ; Cheng CC; Yang CR; Liou JP
    Eur J Med Chem; 2017 Jan; 125():1268-1278. PubMed ID: 27886544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
    Hiriyan J; Shivarudraiah P; Gavara G; Annamalai P; Natesan S; Sambasivam G; Sukumaran SK
    Anticancer Res; 2015 Jan; 35(1):229-37. PubMed ID: 25550555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma.
    Thelen P; Krahn L; Bremmer F; Strauss A; Brehm R; Loertzer H
    Int J Mol Med; 2013 Feb; 31(2):339-46. PubMed ID: 23292124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 1,2:5,6-dianhydrogalactitol inhibits human glioma cell growth in vivo and in vitro by arresting the cell cycle at G
    Peng C; Qi XM; Miao LL; Ren J
    Acta Pharmacol Sin; 2017 Apr; 38(4):561-570. PubMed ID: 28216618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel hydroxysuberamide derivative potentiates MG132-mediated anticancer activity against human hormone refractory prostate cancers--the role of histone deacetylase and endoplasmic reticulum stress.
    Chen YC; Huang WJ; Hsu JL; Yu CC; Wang WT; Guh JH
    Prostate; 2013 Sep; 73(12):1270-80. PubMed ID: 23813634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triptonide acts as a novel antiprostate cancer agent mainly through inhibition of mTOR signaling pathway.
    Dong F; Yang P; Wang R; Sun W; Zhang Y; Wang A; Chen M; Chen L; Zhang C; Jiang M
    Prostate; 2019 Aug; 79(11):1284-1293. PubMed ID: 31212374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.